Pharma Co. Pumped Stock By Hiding Drug Failures, Suit Says

A proposed class of investors hit Corbus Pharmaceutical Holdings Inc. and two of its top executives with a securities suit in Massachusetts federal court Tuesday alleging that the company and its officers concealed negative results in clinical trials of its flagship drug…

Read this piece in its entirety at Law360.